两剂新冠疫苗接种后FDG PET/CT示双侧高代谢腋窝淋巴结病动态演变
一名50岁女性IV期乙状结肠腺癌患者在新辅助化疗/免疫治疗及乙状结肠造口后行FDG PET/CT再分期,除已知乙状结肠肿块和腹盆腔淋巴结转移外,还见双侧不对称高代谢腋窝淋巴结病,为结肠癌非典型播散模式。进一步询问发现患者在此前2个月内接种了两剂新冠疫苗。作者讨论了新冠疫苗接种后免疫原性淋巴结高代谢,并建议纳入疫苗接种史以辅助PET/CT判读,尤其在累及腋窝的恶性肿瘤中。
要点
- IV期乙状结肠腺癌患者再分期FDG PET/CT见双侧不对称高代谢腋窝淋巴结病。
- 结肠癌腋窝淋巴结转移不典型,追问发现患者2个月内接种两剂新冠疫苗。
- 作者提出将疫苗接种史纳入PET/CT判读,尤其对累及腋窝的恶性肿瘤。
核心结论
- 新冠疫苗接种后可出现免疫原性淋巴结高代谢,判读FDG PET/CT时应结合疫苗接种史,尤其在累及腋窝的恶性肿瘤中。
研究设计与样本
- 本文为病例报告,描述一名50岁女性IV期乙状结肠腺癌患者在新辅助化疗/免疫治疗及乙状结肠造口后行FDG PET/CT再分期的影像所见与临床经过。
主要发现
- FDG PET/CT示已知乙状结肠肿块和腹盆腔淋巴结转移处FDG摄取。
- 同时见双侧不对称高代谢腋窝淋巴结病,为结肠癌非典型播散模式。
- 进一步了解发现患者在此前2个月内接种了两剂新冠疫苗。
临床怎么用
- 作者提出将疫苗接种史纳入PET/CT判读,以辅助鉴别淋巴结高代谢的原因,尤其在累及腋窝的恶性肿瘤中。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 50-year-old woman with stage IV sigmoid adenocarcinoma presented for restaging FDG PET/CT status post neoadjuvant chemotherapy/immunotherapy and diverting sigmoid colostomy. FDG PET/CT demonstrated FDG uptake in the known sigmoid mass and in abdominopelvic lymph node metastases. Bilateral, asymmetric, hypermetabolic axillary lymphadenopathy was also observed, an atypical pattern of spread for colon cancer. Further investigation revealed the patient had received both doses of COVID-19 vaccine in the 2 months prior to presentation. The authors discuss immunogenic nodal hypermetabolism following vaccination against COVID-19 and incorporating vaccination history to aid in PET/CT interpretation, especially in malignancies involving the axillae.
引用
- Weeks JK, O'Brien SR, Rosenspire KC, et al. Evolving Bilateral Hypermetabolic Axillary Lymphadenopathy on FDG PET/CT Following 2-Dose COVID-19 Vaccination. Clin Nucl Med. 2021. PMID: 34735411. doi:10.1097/RLU.0000000000003711
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。